International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationExternal Pelvic and Vaginal Irradiation Versus Vaginal Irradiation Alone as Postoperative Therapy in Medium-Risk Endometrial Carcinoma—A Prospective Randomized Study
Introduction
Five prospective randomized studies conducted since 1980 are presented to elucidate the value of external beam pelvic radiotherapy after surgery in early-stage endometrial carcinoma (including the study by Alders et al. [Aalders] [1], Postoperative Radiation Therapy in Endometrial Carcinoma protocol 1 [PORTEC-1], Gynecologic Oncology Group study 99 [GOG-99], A Study in the Treatment of Endometrial Cancer (ASTEC/EN.5), and PORTEC-2 [2-5]). In three of these studies, vaginal brachytherapy (VBT) was also part of the treatment (Aalders, ASTEC/EN.5, PORTEC-2) 1, 4, 5, and in the other two studies (PORTEC-1, GOG-99) 2, 3, external irradiation alone was compared, with no further treatment after primary surgery. The treated populations varied in these studies from groups with no defined risk (Aalders) (1) to a mixture of low-risk (PORTEC-1, GOG-99) 2, 3, medium-risk (PORTEC-1, GOG-99, ASTEC/EN.5, PORTEC-2) 2, 3, 4, 5, and high-risk cases (ASTEC/EN.5) (4). Types of primary surgery and staging also varied from no staging at all (Aalders, PORTEC-1, ASTEC/EN.5, PORTEC-2) 1, 2, 4, 5 to staging with lymph node sampling or complete lymphadenectomy (GOG-99, ASTEC/EN.5) 3, 4. Subgroup analyses performed within the framework of these studies suffered from low power and no level 1 data are presented for well-defined medium-risk and high-risk groups. The general conclusions drawn from these studies are a significantly lower rate of locoregional pelvic recurrences, similar survival rates, and increased bowel toxicity after external pelvic irradiation. The problems seem to be vaginal recurrences, distant metastases, and quality of life. VBT is a more nontoxic alternative to external beam radiotherapy (EBRT) in preventing vaginal recurrences (PORTEC-2 and PORTEC-2 quality of life) 5, 6, and chemotherapy is probably required to reduce the number of distant metastases and to improve survival (7).
A prospective randomized trial is presented from five Swedish gynecological cancer centers to compare VBT alone with a combination of VBT and external beam pelvic irradiation in a well-defined group of medium-risk endometrial carcinomas. Thus, this study differs from all of the five published studies presented above.
The primary study endpoint was locoregional tumor control (pelvic recurrences and vaginal recurrences) and overall survival rate. Secondary endpoints were cancer-specific survival rate, recurrence-free interval and survival, and toxicity.
Section snippets
Patients
Five Swedish cancer centers (Gothenburg, Örebro, Umeå, Uppsala, and Stockholm) recruited patients with medium-risk International Federation of Gynecology and Obstetrics (FIGO) Stage IA-IC endometrial carcinomas into this prospective, randomized, and controlled study. The period of recruitment was from January 1997 through February 2008. In all, 562 patients (arm A = 285 and arm B = 277 patients) were included in the trial. At the time of follow-up, 527 patients were evaluable for analysis.
Recurrence rate
The overall recurrence rate for the complete series was 42 of 527 cases or 8.0%. In the group treated with EBRT plus vaginal irradiation (arm A), 15 recurrences in 264 cases (5.7%) were recorded; and in the group treated with vaginal irradiation alone (arm B), 27 recurrences in 263 cases (10.3%) were recorded (Pearson chi-square, p = 0.052). Five vaginal recurrences (1.9%) were diagnosed in the combined treatment arm and 7 recurrences after vaginal irradiation alone (2.7%) (Pearson chi-square, p
Discussion
Postoperative treatments of FIGO Stage I endometrial carcinoma have been vividly discussed and also studied in a number of randomized trials during the last decade 1, 2, 3, 4, 5. Before that, no consensus existed with regard to type of therapy, but the situation has changed, and our evidence-based knowledge in this field has improved substantially. However, different conclusions are still drawn from available study data, and the optimal treatment of the various risk groups is continuously
Conclusions
In this study, we have shown that combined EBRT and VBT was superior to VBT alone in improving locoregional tumor control in medium-risk endometrial cancer patients. This might be of benefit to the patients. However, questions of cost effectiveness, radiation-induced side effects (17), and lack of a survival benefit for this risk group must be taken into account.
Future radiotherapy studies of this risk group of endometrial carcinoma patients should address new and improved techniques (e.g.,
References (23)
- et al.
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma
Lancet
(2000) - et al.
A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecol Oncol Group study
Gynecol Oncol
(2004) - et al.
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial
Lancet
(2010) - et al.
Survival after relapse in patients with endometrial cancer: Results from a randomized trial
Gynecol Oncol
(2003) - et al.
Should the presence of lymph vascular space involvement be use to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?
Gynecol Oncol
(2002) - et al.
The morbidity of treatment for patients with Stage I endometrial cancer: Results from a randomized trial
Int J Radiat Oncol Biol Phys
(2001) - et al.
Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy
Int J Radiat Oncol Biol Phys
(2001) - et al.
Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging
Gynecol Oncol
(2008) - et al.
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
Int J Radiat Oncol Biol Phys
(1995) - et al.
Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients
Obstet Gynecol
(1980)
Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and metaanalysis
Lancet
Cited by (0)
Conflict of interest: none.